Combination antiretroviral therapy (ART) is effective in inhibiting HIV infection and reducing rates of transmission, while also improving the quality of life and increasing the life expectancy of patients with HIV/AIDS. However, there are significant drawbacks to the antiviral drug therapy, including potential drug resistance, toxic side effects, and cost of daily medication. Moreover, individuals on long-term treatment can have significant cardiac changes, such as, loss of bone density, premature aging as well as other complications; the collective of which are sufficiently significant to consider the development of novel alternative therapies. The proposed study will focus on gene therapy strategies to establish an HIV-resistant immune system. Our strategy involves the expression of multiple anti-HIV genes in hematopoietic stem/progenitor cells (HSPCs) that are the precursors for HIV-susceptible cells. Hence, the overriding goal of this proposal is develop a combinatorial anti-HIV gene therapy that inhibits many aspects of the virus life cycle, from virus entry to viral expression an production, which will improve upon the anti-HIV efficacy, suppress viral mutant escape, and abate cellular toxicity. This goal builds on our prior work, in which we developed and clinically evaluated an anti-HIV lentiviral vector (rHIV7-shI-TAR-CCR5RZ) that expressed three anti-HIV small RNAs, including a short hairpin RNA (shRNA) targeting the tat/rev of HIV-1 mRNA transcripts, a ribozyme targeting CCR5 mRNA, and a nucleolar-localizing TAR decoy, which represented the first successful demonstration of engraftment and long-term maintenance of gene-modified HSPCs in an HIV infected population. In the previous funding period, we extend this approach by developing the MCM7-S1-S2M-S3B- tRNASer-CCR5sh lentiviral vector, which expresses three anti-HIV siRNAs as miRNA mimics from the MCM7 intron and a fourth CCR5 shRNA from a novel tRNASer promoter. In primary cell and humanized mouse studies, we demonstrated that this design is safer and more efficacious that the original combinatorial lentiviral vector, and we are now preparing it for clinical evaluation. In the proposed studies for this project, we will apply this same innovation to develop a new generation of highly potent anti-HIV lentiviral vectors that are designed to be safer, more efficacious, and more resistant to viral escape than any previous generation of anti-HIV vectors and are capable of virus-independent enrichment of vector transduced HSPCs.
In Specific Aim 1 we will test combinations of anti-HIV genes for anti HIV activity and resistance to mutational escape in long term T-cell and hematopoietic cell culture. By combining our most potent multi-resistant shRNA, a tRNA-aptamer, and TRIM5? components, we will create novel combinatorial lentiviral vectors, designed to be highly effective, resistant to mutational escape, and nontoxic to cells.
In Specific Aim 2, we will optimize vector packaging, transduction, and enrichment of transduced HSPCs. In the pre-clinical development of anti-HIV lentiviral vectors, it is imperative to design vectors that are highly potent against HIV without compromising vector packaging and the feasibility of scale-up.
This aim will address these concerns, as well as investigating methods for improving transduction efficiencies, selection of transduced HSPCs.
In Specific Aim 3, we will test vector transduced hematopoietic stem cells in a NSG humanized mouse model to evaluate the efficacy, safety, and toxicity of new combinatorial lentiviral vectors in CD34+ HSPCs. Because we are developing combinatorial vectors that incorporate new anti-HIV genes and novel expression strategies, we will utilize the humanize NSG mouse model to address potential concerns regarding the hematopoietic toxicity, interferon activation, antiviral activity, and overal safety. We will also evaluate long-term antiviral protection and resistance to mutational escape for each new vector in mice challenged with R5-tropic HIV-1BaL or R5/X4-tropic HIV-189.6.

Public Health Relevance

Combinatorial antiretroviral therapies (ART) inhibit HIV replication, reduce the rates of transmission, and improve life expectancy. Unfortunately, ART is non-curative, and nearly all HIV-infected individuals on ART will need to maintain their medications for the entirety of their lives, resulting in considerable expense, development of resistance, and sometimes the toxic side effects of these drugs. Analogous to ART cocktails, the proposed studies capitalize on the potential of using a combinatorial gene-based approach, where multiple anti-HIV genes protect cells from HIV infection and replication. This combinatorial gene-based approach is designed to disrupt multiple viral pathways to reduce HIV replication and decrease the probability of resistance. The long term goal of these studies is the establishment of potent, nontoxic combinations of anti-HIV genes for the treatment of HIV-1 infection.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project (R01)
Project #
Application #
Study Section
AIDS Discovery and Development of Therapeutics Study Section (ADDT)
Program Officer
Poon, Betty
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Beckman Research Institute/City of Hope
United States
Zip Code
Pang, Ka Ming; Castanotto, Daniela; Li, Haitang et al. (2018) Incorporation of aptamers in the terminal loop of shRNAs yields an effective and novel combinatorial targeting strategy. Nucleic Acids Res 46:e6
Reebye, Vikash; Huang, Kai-Wen; Lin, Vivian et al. (2018) Gene activation of CEBPA using saRNA: preclinical studies of the first in human saRNA drug candidate for liver cancer. Oncogene 37:3216-3228
Zhou, Jiehua; Lazar, Daniel; Li, Haitang et al. (2018) Receptor-targeted aptamer-siRNA conjugate-directed transcriptional regulation of HIV-1. Theranostics 8:1575-1590
Yoon, Sorah; Wu, Xiwei; Armstrong, Brian et al. (2018) An RNA Aptamer Targeting the Receptor Tyrosine Kinase PDGFR? Induces Anti-tumor Effects through STAT3 and p53 in Glioblastoma. Mol Ther Nucleic Acids 14:131-141
Satheesan, Sangeetha; Li, Haitang; Burnett, John C et al. (2018) HIV Replication and Latency in a Humanized NSG Mouse Model during Suppressive Oral Combinational Antiretroviral Therapy. J Virol 92:
Hori, Shin-Ichiro; Herrera, Alberto; Rossi, John J et al. (2018) Current Advances in Aptamers for Cancer Diagnosis and Therapy. Cancers (Basel) 10:
Yoon, Sorah; Armstrong, Brian; Habib, Nagy et al. (2017) Blind SELEX Approach Identifies RNA Aptamers That Regulate EMT and Inhibit Metastasis. Mol Cancer Res 15:811-820
Zhou, Jiehua; Rossi, John (2017) Aptamers as targeted therapeutics: current potential and challenges. Nat Rev Drug Discov 16:181-202
Song, Min-Sun; Rossi, John J (2017) Molecular mechanisms of Dicer: endonuclease and enzymatic activity. Biochem J 474:1603-1618
Takahashi, Mayumi; Wu, Xiwei; Ho, Michelle et al. (2016) High throughput sequencing analysis of RNA libraries reveals the influences of initial library and PCR methods on SELEX efficiency. Sci Rep 6:33697

Showing the most recent 10 out of 106 publications